This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Mucci, L. A. Articles by Rubin, M. A. Search for Related Content PubMed PubMed Citation Articles by Mucci, L. A. Articles by Rubin, M. A. Related Collections Oncogenesis Oncogenesis: Biomarkers

Nine-Gene Molecular Signature Is Not Associated with Prostate Cancer Death in a Watchful Waiting Cohort

¹ Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School; ² Department of Epidemiology, Harvard School of Public Health; ³ Department of Pathology, Harvard Medical School; ⁴ Department of Pathology, Brigham and Women's Hospital; ⁵ Dana-Farber Cancer Institute, Boston, Massachusetts; ⁶ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; ⁷ Bioinformatics Group, SRA, ITC-irst, Trento, Italy; ⁸ Department of Urology, Örebro University Hospital, Örebro, Sweden; ⁹ Regional Oncologic Centre, Uppsala University, Uppsala, Sweden; ¹⁰ Department of Pathology, University of Ulm, Ulm, Germany; and ¹¹ Department of Pathology, Weill Medical Center of Cornell University, New York, New York

Requests for reprints: Lorelei A. Mucci, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 3rd Floor, 181 Longwood Avenue, Boston, MA 02115. Phone: 617-525-2132; Fax: 617-525-2008. E-mail: lmucci{at}hsph.harvard.edu

Tumor molecular markers hold promise to distinguish potentially lethal from indolent prostate cancer and to guide treatment choices. A previous study identified a nine-gene molecular signature in tumors associated with prostate-specific antigen relapse after prostatectomy. We examined this molecular model in relation to prostate cancer death among 172 men with initially localized disease. We quantified protein expression of the nine genes in tumors to classify progression risk. Accounting for clinical prognostic factors, the nine-gene model did not provide discrimination to predict lethal and indolent prostate cancer. (Cancer Epidemiol Biomarkers Prev 2008;17(1):249–51)